ATXS
Price
$11.14
Change
+$0.02 (+0.18%)
Updated
Sep 27 closing price
39 days until earnings call
NGNE
Price
$40.33
Change
+$1.15 (+2.94%)
Updated
Sep 27 closing price
Ad is loading...

ATXS vs NGNE

Header iconATXS vs NGNE Comparison
Open Charts ATXS vs NGNEBanner chart's image
Astria Therapeutics
Price$11.14
Change+$0.02 (+0.18%)
Volume$347.14K
CapitalizationN/A
Neurogene
Price$40.33
Change+$1.15 (+2.94%)
Volume$93.11K
CapitalizationN/A
View a ticker or compare two or three
ATXS vs NGNE Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NGNE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ATXS vs. NGNE commentary
Sep 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and NGNE is a Hold.

COMPARISON
Comparison
Sep 29, 2024
Stock price -- (ATXS: $11.46 vs. NGNE: $32.82)
Brand notoriety: ATXS and NGNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 101% vs. NGNE: 62%
Market capitalization -- ATXS: $628.58M vs. NGNE: $524.03M
ATXS [@Biotechnology] is valued at $628.58M. NGNE’s [@Biotechnology] market capitalization is $524.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.37B to $0. The average market capitalization across the [@Biotechnology] industry is $3.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileNGNE’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • NGNE’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than NGNE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 7 TA indicator(s) are bullish while NGNE’s TA Score has 2 bullish TA indicator(s).

  • ATXS’s TA Score: 7 bullish, 2 bearish.
  • NGNE’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than NGNE.

Price Growth

ATXS (@Biotechnology) experienced а -5.60% price change this week, while NGNE (@Biotechnology) price change was -8.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.80%. For the same industry, the average monthly price growth was +5.34%, and the average quarterly price growth was -8.06%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 07, 2024.

NGNE is expected to report earnings on Nov 14, 2023.

Industries' Descriptions

@Biotechnology (+3.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($629M) has a higher market cap than NGNE($524M). NGNE YTD gains are higher at: 69.350 vs. ATXS (49.219). ATXS has less debt than NGNE: ATXS (168K) vs NGNE (15.7M).
ATXSNGNEATXS / NGNE
Capitalization629M524M120%
EBITDAN/AN/A-
Gain YTD49.21969.35071%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total Cash18.6MN/A-
Total Debt168K15.7M1%
FUNDAMENTALS RATINGS
ATXS vs NGNE: Fundamental Ratings
ATXS
NGNE
OUTLOOK RATING
1..100
1657
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4834
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a2

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (64) in the Biotechnology industry is in the same range as NGNE (75) in the null industry. This means that ATXS’s stock grew similarly to NGNE’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NGNE (100) in the null industry. This means that ATXS’s stock grew similarly to NGNE’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as NGNE (99) in the null industry. This means that ATXS’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's Price Growth Rating (34) in the null industry is in the same range as ATXS (48) in the Biotechnology industry. This means that NGNE’s stock grew similarly to ATXS’s over the last 12 months.

NGNE's P/E Growth Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that NGNE’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSNGNE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Momentum
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
MACD
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
TrendWeek
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
TrendMonth
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
Advances
ODDS (%)
Bullish Trend about 1 month ago
0%
N/A
Declines
ODDS (%)
Bearish Trend about 2 months ago
0%
Bearish Trend about 2 months ago
87%
BollingerBands
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Aroon
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NGNE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.14-0.28
-1.20%
GameStop Corp
TSLA210.60-3.51
-1.64%
Tesla
SPY552.08-11.60
-2.06%
SPDR® S&P 500® ETF Trust
AAPL222.77-6.23
-2.72%
Apple
BTC.X57431.023000-1681.457000
-2.84%
Bitcoin cryptocurrency

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KALV. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KALV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-6.30%
KALV - ATXS
41%
Loosely correlated
-7.62%
ADCT - ATXS
38%
Loosely correlated
-5.86%
FULC - ATXS
37%
Loosely correlated
-5.26%
SNDX - ATXS
37%
Loosely correlated
-0.05%
INZY - ATXS
36%
Loosely correlated
-5.60%
More

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
-12.29%
BRNS - NGNE
51%
Loosely correlated
N/A
RNAZ - NGNE
48%
Loosely correlated
-11.66%
BPTSY - NGNE
38%
Loosely correlated
N/A
CLRB - NGNE
27%
Poorly correlated
-2.73%
ATXS - NGNE
21%
Poorly correlated
-6.30%
More